Cipla gets exclusive rights to market ophthalmic drug across 11 countries

APP13007 is a novel, patent protected and USFDA approved ophthalmic product. It offers a convenient twice-daily dosing regimen for 14 days without tapering, providing rapid and sustained relief from inflammation and pain. This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits.

"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of innovative medicines and look forward to working together to provide our novel therapy to ocular surgery patients to their audience." said Erick Co, President and CEO of Formosa Pharmaceuticals.

Commenting on this partnership, Achin Gupta, Global Chief Operating Officer, Cipla said, "The partnership with Formosa Pharmaceuticals marks a significant milestone for Cipla, as it is our first multi-regional licensing agreement in ophthalmology. It reinforces our commitment to bringing cutting-edge treatments to patients worldwide. With exclusive rights to market APP13007 across 11 countries, we are excited to expand access to this innovative therapy and strengthen our ophthalmology portfolio. We look forward to leveraging Cipla's strong commercial presence to make a meaningful impact in post-operative eye care."

Cipla's ophthalmology division is focused on developing therapies and technologies for glaucoma, dry eye disease, ocular infections and retinal diseases. The strategic licensing agreement with Formosa Pharmaceuticals includes upfront payments, royalty milestones, and additional value-driven considerations throughout its term.